Keros Therapeutics (KROS) Assets Average (2020 - 2025)

Keros Therapeutics (KROS) has 6 years of Assets Average data on file, last reported at $540.4 million in Q4 2025.

• For the quarter ending Q4 2025, Assets Average fell 9.57% year-over-year to $540.4 million; the trailing twelve-month figure through Dec 2025 stood at $540.4 million (down 9.57% YoY), and the FY2025 full-year result was $477.0 million, down 3.25% from the prior year.
• Assets Average for Q4 2025 stood at $540.4 million, down from $750.0 million in the prior quarter.
• Across five years, Assets Average topped out at $770.9 million in Q2 2025 and bottomed at $230.9 million in Q2 2022.
• The 5-year median for Assets Average is $346.9 million (2023), against an average of $408.4 million.
• The widest annual swing landed in 2021, when Assets Average soared 636.82%; it then slipped 9.57% in 2025.
• A 5-year view of Assets Average shows it stood at $242.6 million in 2021, then gained by 15.28% to $279.7 million in 2022, then gained by 24.48% to $348.1 million in 2023, then surged by 71.65% to $597.6 million in 2024, then decreased by 9.57% to $540.4 million in 2025.
• The last three Assets Average figures came in at $540.4 million (Q4 2025), $750.0 million (Q3 2025), and $770.9 million (Q2 2025), per Business Quant data.

Peer Comparison